Chilosi M, Semenzato G, Cetto G, Ambrosetti A, Fiore-Donati L, Perona G, Berton G, Lestani M, Scarpa A, Agostini C
Istituto di Anatomia Patologica and Patologia Generale, Universita' di Verona, Italy.
Blood. 1987 Nov;70(5):1530-5.
In this study we provide evidence that the sera of patients with hairy cell leukemia (HCL) contain a factor that can prevent the binding of a monoclonal antibody specific for interleukin-2 receptor (IL-2R) to its target. This factor corresponds to the soluble form of IL-2R (sIL-2R), as assessed by a specific enzyme-linked immunosorbent assay test, and appears to be released by neoplastic hairy cells. The serum sIL-2R levels were very high at diagnosis and significantly reduced during recombinant alpha-interferon (rIFN alpha 2) therapy. Values of sIL-2R appeared to be inversely related to the natural killer in vitro function displayed by peripheral blood mononuclear cells from the same patients. The presence of sIL-2R in the serum of patients with HCL might be involved in the impairment of cell-mediated immunity observed in these patients and could represent a valuable marker for monitoring different phases of the disease and for modulating IFN therapy.
在本研究中，我们提供证据表明，毛细胞白血病（HCL）患者的血清中含有一种因子，该因子可阻止特异性针对白细胞介素-2受体（IL-2R）的单克隆抗体与其靶标结合。通过特异性酶联免疫吸附测定试验评估，该因子对应于IL-2R的可溶性形式（sIL-2R），并且似乎由肿瘤性毛细胞释放。血清sIL-2R水平在诊断时非常高，在重组α干扰素（rIFNα2）治疗期间显著降低。sIL-2R的值似乎与来自同一患者外周血单个核细胞在体外显示的自然杀伤功能呈负相关。HCL患者血清中sIL-2R的存在可能与这些患者中观察到的细胞介导免疫受损有关，并且可能代表用于监测疾病不同阶段和调节干扰素治疗的有价值标志物。
